NCT05113069View on ClinicalTrials.gov

A Study of SHR-A1912 for Injection in Patients With B Cell Lymphomas

PHASE1Enrolling by invitationINTERVENTIONAL

Enrollment

170

Participants

Timeline

Start Date

December 22, 2021

Primary Completion Date

March 31, 2024

Study Completion Date

March 30, 2025

Conditions

B Cell Lymphoma

Interventions

DRUG

SHR-A1912

SHR-A1912, dose escalation and expansion.

Trial Locations (1)

100142

Beijing Cancer Hospital, Beijing

All Listed Sponsors

lead

Shanghai Hengrui Pharmaceutical Co., Ltd.

INDUSTRY